30 closest matches · ranked by relevance
Aortic Valve Stenosis · Cardiovascular Diseases · Heart Valve Diseases
Primary: Rate of Patients With at Least One Prosthetic Leaflet With >50% Motion Reduction as Assessed by Cardiac 4DCT-scan — 11; 2 Participants — p=0.01
Native and Valve in Valve Aortic Valve Failure
Primary: Number of Participants With Procedure Success, Measured at Exit From the Catheterization Laboratory — 28 participants
Valvular Heart Disease · Aortic Valve Failure
Primary: Number of Participant That Experienced Technical Success With the TELLTALE Guidewire System — 90 Participants
Aortic Valve Stenosis
Primary: Change in the Late-Life Function and Disability Instrument (LLFDI) Score — 53.2; 52.0; 52.9; 58.9 units on a scale
Transcatheter Aortic Valve Implantation
Primary: Post Procedure Hospital Length of Stay — 4.8; 3.5 days
Aortic Valve Stenosis
Primary: All-cause Mortality Rate — 1.7 percentage of participants
Atrial Fibrillation · Aortic Valve Stenosis
Primary: Composite of All-cause Mortality, Stroke and Bleeding — 60; 64 Participants
Aortic Stenosis
Primary: Number of Patients Where the Device Accessed, Deployed and Was Positioned in the Aortic Arch (Device Performance) — 33 Participants
Aortic Stenosis · Coronary Artery Disease
Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio
Stroke
Primary: The Rate of Stroke Through 72 Hours Post TAVR Procedure or Discharge (Whichever Comes First) — 34; 43 Participants
Aortic Valve Stenosis
Primary: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate — 0.099 probability of events at 30 days
Aortic Stenosis · Inflammation · Thrombosis
Primary: Platelet Reactivity — 275.5; 251; 234; 128.5 Platelet Reactivity Units
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Aortic Valve Stenosis
Primary: Composite Major Adverse Event (MAE) Free Rate — 54.2; 48.1; 51.6 Percentage of subjects
Risk of Coronary Obstruction Following Transcatheter Aortic Valve Replacement (TAVR) Procedure
Primary: (Number of Patients With) ShortCut™ Device- and/or ShortCut™ Procedure-related Mortality and All Cause Stroke — 0; 1; 59 Participants
Symptomatic Aortic Stenosis
Primary: All Cause Mortality — 8 Participants
Aortic Stenosis
Primary: All-cause Mortality at 30 Days by Percent — 2.5 percentage of partcipants
Severe Aortic Stenosis
Primary: Extreme Risk: All-cause Death or Major Stroke; High Risk Surgical: All-cause Mortality — 22.5; 30.8; 17.8 percentage of participants, Kaplan-Meier
Severe Aortic Stenosis
Primary: Extreme Risk: All-cause Death or Major Stroke; High Risk Surgical: All-cause Mortality — 26.0; 39.3; 14.1; 18.9 percentage of participants, Kaplan-Meier — p=<0.0001
Eisenmenger Syndrome
Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants
Aortic Valve Stenosis
Primary: Percentage of Participants With All-cause Mortality — 12.1 percentage of participants
Severe Symptomatic Calcified Native Aortic Valve Stenosis
Primary: Reduction in Median Total New Lesion Volume in Protected Territories Between Test and Control Arms as Assessed by DW-MRI at Day 2-7 Post-procedure. — 109.1; 174 mm3
Symptomatic Aortic Stenosis
Primary: Primary Safety Endpoint - Composite Safety Endpoint Based on MACCE — 25 Participants
Coronary Artery Disease
Primary: Coronary Flow Reserve (CFR) — 2.23 Ratio
Aortic Valve Stenosis · Aortic Valve Failure · Aortic Insufficiency
Primary: Primary Safety Endpoint: The Rate of All-cause Mortality, Disabling Stroke, Life-threatening Bleeding Requiring Blood Transfusion, Acute Kidney Injury (AKI) Requiring…
Aortic Valve Stenosis
Primary: Percentage of MAE Free Subjects — 10 Participants
Arterial Occlusion · Cardiovascular Diseases · Hematoma
Primary: Time to Hemostasis — 5.11; 4.3 minutes
Aortic-valve Replacement
Primary: Reduction in Leaflet Motion — 12 Participants
Coronary Artery Disease
Primary: Number of Participants With Radial Artery Occlusion — 4; 2 Participants
Transcatheter Aortic Valve Replacement · Closure Technique
Primary: Number of Participants With Main Access-related Bleeding and Vascular Complications — 47; 42 Participants